TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months~* Insulin naïve subjects (Allowed are: previous short term insulin treatment up to 14 days; treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days)~* Current treatment: metformin monotherapy or metformin in any combination with an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitor, alfa-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3 months prior to randomisation (Visit 2) with the minimum doses stated: metformin: alone or in combination (including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000 mg daily), insulin secretagogue (sulfonylurea or glinide): minimum half of the daily maximal dose according to local labelling, DPP-IV inhibitor: minimum 100 mg daily or according to local labelling, alfa-glucosidase-inhibitors (acarbose): minimum half of the daily maximal dose or maximum tolerated dose~* HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive) by central laboratory analysis~* BMI (Body Mass Index) below or equal to 40.0 kg/m\^2~Exclusion Criteria:~* Treatment with TZDs (thiazoledinedione), or GLP-1 (glucagon-like peptide 1) receptor agonists within the last 3 months prior to Visit 1 (screening)~* Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic corticosteroids, beta-blockers, MAO (monoamine oxidase) inhibitors~* Cardiovascular disease within the last 6 months prior to Visit 1 (screening) defined as stroke; decompensated heart failure NYHA (New York Heart Association) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Any clinically significant disease or disorder, except for conditions associated with type 2 diabetes mellitus, which in the Investigator's opinion could interfere with the results of the trial~* Previous participation in this trial. Participation is defined as randomised. Re-screening of screening failures is allowed only once within the limits of the recruitment period~* Known or suspected hypersensitivity to trial product(s) or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Degludec (Type: EXPERIMENTAL): None
- Insulin Glargine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Antihypertensive Drugs on Severity of Anaphylaxis and Side-effects During Venom Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of systemic sting reaction (≥ grade I according the classification by Ring and Messmer)~* age 35 to 85 years~Exclusion Criteria:~* absolute contraindications for VIT~* pretreatment with Omalizumab

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- patients with a history of an anaphylactic sting reaction (Type: None): At Visit 1, patients will be included after carefully reviewing all inclusion and exclusion criteria. All data concerning the index sting, laboratory parameters like immunoglobulin E (IgE) and tryptase levels and skin test results will be recorded as well as the concomitant diseases and medication. Visit 2 will be performed after VIT updosing is finished. At this Visit data concerning the immunotherapy - premedication, preparation, updosing protocol, the outcome of possible large, local reactions (LLR) and systemic reactions (SR) and changes in diseases and medication will be recorded. One year after reaching the maintenance dose, Visit 3 will be performed. At this Visit data concerning the maintenance phase like premedication and possible side effects will be recorded as well as the outcome of insect stings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed study B2061014 and who in the investigator's opinion would benefit from long term treatment with DVS SR~* Willingness and ability to comply with scheduled visits, treatment plan and procedures~Exclusion Criteria:~* Subject requires precaution against suicide~* Subject not in a generally healthy condition

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine Succinate Sustained-Release (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent by subject's parents or subject's legally acceptable representative before any trial related activities. Trial related activities are any procedures that would not have been performed during the normal management of the subject~* Age 1 to less than 6 years old at the time of enrolment~* Congenital FXIII subunit-A deficiency previously documented by genotyping or evaluated by genotyping through blood sampling at screening visit~* Body weight at least 10 kg~Exclusion Criteria:~* Known antibodies to FXIII~* Hereditary or acquired coagulation disorder other than FXIII A-subunit congenital deficiency~* Platelet count (thrombocytes) of less than 50 × 10\^9/L (at screening visit)~* Previous history of autoimmune disorder involving autoantibodies e.g., systemic lupus erythematosus~* Previous history of arterial or venous thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis~* Known or suspected allergy to trial product or related products~* Any surgical procedure in the 30 days prior to enrolment and any planned surgery during the trial period~* Any disease or condition which, judged by the Investigator, could imply a potential hazard to the subject or interfere with the trial participation or trial outcome including renal and/or liver dysfunction

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- recombinant factor XIII (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 19 years of age~* Patient who undergoes gastrectomy (total, distal or proximal gastrectomy)~* D1+ or D2 lymph node dissection~* Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale~* Written informed consent~Exclusion Criteria:~* Patients with cholangitis, cholecystitis, non-functional gall bladder, or biliary obstruction~* Presence of gallstones on ultrasonography and/or CT~* History of previous cholecystectomy~* Patients undergoing pylorus-preserving gastrectomy~* Pregnant or lactating women and fertile women who is not using proper contraceptive method~* Patients with history of drug or alcohol abuse within 5 years ago

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DWJ1319 300 mg BID (Type: EXPERIMENTAL): DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
- DWJ1319 300 mg QD (Type: EXPERIMENTAL): DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, orally, twice daily (BID) for up to 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison the Postoperative Quality of Recovery Between Neostigmine and Sugammadex in Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia -Randomized Controlled Trial-

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients aged over 60 years who are scheduled for trans pars plana vitrectomy with general anesthesia~Exclusion Criteria:~* Neuromuscular disease~* History of malignant hyperthermia~* Significant renal or hepatic dysfunction~* Allergy to sugammadex or rocuronium~* BMI \> 30kg/m2~* History of medication which affect neuromuscular blocker such as anti-convulsants, magnesium

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex group (Type: EXPERIMENTAL): After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
- Neostigmine group (Type: ACTIVE_COMPARATOR): After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected men and women at least 18 years of age~* On stable HAART for previous three months and without anticipated changes in their HAART regimen throughout the duration of the study~* Fasting triglycerides \> 150 mg/dl and \< 1,500 mg/dl~* Participants may be on lipid lowering therapy; if on lipid lowering therapy, therapy must be stable for 8 weeks and cannot be changes during the course of the study~* Participants may be on beta blockers (e.g., Atenolol, Metoprolol, Propranolol), Estrogens (e.g.,Estinyl;Estrace;Estraderm) and Thiazides (water pills), however therapy with these agents must be stable for 8 weeks before starting the study and cannot be altered while on the study unless deemed medically necessary by the participant's medical provider and approved by Dr. Wanke~* Female participants of reproductive age must not be pregnant (negative test) or lactating at screening and throughout the trial and agree to use 2 methods of barrier contraception for the course of the trial and 2 months after the trial unless they are surgically sterilized (tubal ligation or hysterectomy), or post-menopausal with no menses for \> 1 year~* Ability to provide consent~Exclusion Criteria:~* Plasma HIV-1 RNA \> 10,000~* Previous history of atherosclerotic disease or diabetes mellitus~* Change in HAART regimen over three months prior to study entry~* Change in lipid lowering therapy within 2 months~* On chronic anticoagulants such as heparin or coumadin~* On fish oil, omega 3 supplements, or Omacor currently or during the past month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lovaza (Type: ACTIVE_COMPARATOR): Lovaza, dietary counseling
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, dietary counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of 4% Articaine Versus 0.5%Bupivacaine for Ambulatory Surgery Under Supraclavicular Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* upper limb surgery~* ganglion removal~* k wiring~* Carapal tunnel~Exclusion Criteria:~* Coagulopathy.~* infection at site of injection.~* patient refusal.~* hypersensitivity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Articaine group (Type: EXPERIMENTAL): Patients in this group are assigned to recieve 30 ml of Articaine 2%
- Bupivacaine (Type: EXPERIMENTAL): Patients in this group are assigned to recieve 30 ml of bupivacaine 0.5%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic carcinoma of the breast that is progressive~* Premenopausal, defined as any of:~  1. Last menstrual period within 3 months, or~ 2. Post-hysterectomy without bilateral oophorectomy and with follicle-stimulating hormone (FSH) in the premenopausal range, or,~ 3. If tamoxifen administered within the past 3 months, plasma estradiol must be in the premenopausal range~* Either positive estrogen and/or progesterone receptor determination by Immunohistochemistry (IHC) or competitive binding assay on metastatic disease, or if not performed on their metastatic disease a positive result on their primary breast cancer specimen.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~* Granulocytes \> 1500/mm\^3~* Platelets \> 100,000/mm\^3~* Serum glutamic oxaloacetic transaminase (SGOT) \< 2.5 x upper limit of normal~* Total bilirubin \< 1.5 mg/dL~* May have received irradiation to bony sites of disease for pain control or for prevention of fracture. The irradiated site(s) will NOT be evaluable for disease response.~* Must be using effective contraception or not be of childbearing potential~* Signed written informed consent~INCLUSION CRITERIA~* Active, unresolved infection~* Active malignancy other than breast cancer, in situ carcinoma of the cervix, or non-melanomatous skin cancers in the past 5 years~* Prior treatment with an aromatase inhibitor or inactivator~* Prior treatment with an luteinizing hormone-releasing hormone (LH/RH) agonist/antagonist~* Adjuvant chemotherapy within 6 months of study entry.~* Received chemotherapy or hormonal therapy in the 3 weeks prior to enrollment~* Central nervous system metastasis~* Lymphangitic pulmonary metastasis~* Pregnant or lactating

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Anastrozole + Goserelin (Type: EXPERIMENTAL): Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily. No dose attenuation or escalation was allowed for either goserelin or anastrozole.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Effectiveness and Participant Satisfaction Study of a Dermal Filler (of RADIESSE® (+) Lidocaine) in the Treatment of Ageing Signs in the Face

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female greater than or equal to (\>=) 18 years old.~2. Participants seeking for dermal filler/volumising treatment in at least two of the following indications:~   * Nasolabial folds;~  * Marionette lines;~  * Cheek volume loss.~3. Nasolabial folds volume deficit of moderate to very severe intensity (grade 2 to 4) on the Merz Nasolabial Folds Scale with symmetrical rating at Day 1 as determined by the blinded rater and confirmed by the treating investigator afterwards.~4. Marionette lines volume deficit of moderate to very severe intensity (grade 2 to 4) on the Merz Marionette Lines Scale with symmetrical rating at Day 1 as determined by the blinded rater and confirmed by the treating investigator afterwards.~5. Upper cheek volume deficit of moderate to very severe intensity (grade 2 to 4) on the Merz Upper Cheek Fullness Scale with symmetrical rating at Day 1 as determined by the blinded rater and confirmed by the treating investigator afterwards.~At least two of the inclusion criteria 3, 4, and 5 must be fulfilled. Depending on the fulfilled criteria, the respective indications will be treated.~Exclusion Criteria:~1. Any prior treatment with silicone, polymethyl methacrylate, fat injections, poly L-lactic acid or permanent dermal fillers in the face.~2. Any prior facial surgery, including facial plastic surgery, thread lift, any unknown treatment, or any surgical permanent implant that could interfere with performance assessments.~3. Prior treatment within the past 24 months with porcine based collagen fillers or with volumisers (e.g., Belotero® Volume or others) in the area to be treated.~4. Prior treatment within the past 18 months with calcium hydroxylapatite in the area to be treated.~5. Prior treatment within the past 12 months with hyaluronic acid in the area to be treated.~6. Prior treatment within the past 6 months with facial dermal therapies (e.g. epilation, ultraviolet irradiation, radiofrequency, facial ablative or non-ablative laser treatment, microderm abrasion, mechanical or chemical peels, non-invasive skin-tightening \[e.g., Ultherapy, Thermage\] or surgical procedures) or plans to receive this during participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RADIESSE® (+) Lidocaine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age between 5-55 years (inclusive) of either gender.~* Newly diagnosed VL or VL treatment failure confirmed by spleen or bone marrow aspirate.~* Clinical signs and symptoms compatible with VL: fever of over two weeks duration and splenomegaly.~* Biochemical and haematological test values as follows:~  * Haemoglobin \> 5.0g/100mL~ * White blood cell count \> 1 x109/L~ * Platelet count \> 50 x 109/L~ * AST, ALT and alkaline phosphatase \< 3 times upper normal limit~ * Prothrombin time \< 5 seconds above control~ * Serum creatinine levels within normal limits~ * Serum potassium levels within normal limits~* HIV negative~Exclusion Criteria:~* A history of intercurrent or concurrent diseases (e.g. chronic alcohol consumption or drug addiction; renal, hepatic, cardiovascular or central nervous system disease; diabetes; tuberculosis or other infectious or major psychiatric diseases) that may introduce variables affecting the outcome of the study.~* Any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up.~* An abnormal baseline audiogram (presentation with 75 dB or higher at 8KHz or below) and/or a history of significant vestibular or auditory dysfunction.~* Proteinuria (\> 2+).~* A history of allergy or hypersensitivity to aminoglycosides.~* A history of major surgery within the last two weeks.~* Pregnancy or lactation. \[Note: women of childbearing age must use an adequate form of contraception (documented) or agree to a period of sexual abstinence during the treatment phase of the study.\]~* Previous treatment for VL within two weeks of enrolment into the study.~* Prior treatment failures with paromomycin or amphotericin B.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete